Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Humedix Co., Ltd. (200670.KQ)
KRW27,000.00
+1,300.00 (+5.06%)
KR KOE Healthcare Drug Manufacturers - Specialty & Generic
Address
603, 268, Hagui-ro 14056
Anyang-Si, KR
Anyang-Si, KR
CEO
Min-jong Kang
Website
humedix.com
IPO
2014-12-26
ISIN KR7200670008
Description
Humedix Co., Ltd. is a South Korean healthcare enterprise engaged in the research, development, production, and distribution of a diverse array of pharmaceutical goods. Its comprehensive portfolio encompasses non-prescription and prescription medications, active pharmaceutical ingredients, and medical equipment. Beyond pharmaceuticals, the company also supplies cosmetic items, advanced functional synthetic materials, and health-enhancing dietary supplements. Founded in 2002, Humedix Co., Ltd. is headquartered in Anyang-si, South Korea, and was previously known as HVLS Co., Ltd. before adopting its current name in 2010.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW27,000.00
+1,300.00 (+5.06%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
45.6K
Beta
0.34
Float Shares
5.57M
Free Float %
54.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.08% | -15.06% | -20.68% | -38.43% | -38.43% | -31.55% | -32.54% | -7.69% | -17.30% | -32.95% | -1.07% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
27,000.00
DCF (Unlevered)
73,415.40
+171.9%
DCF (Levered)
79,305.91
+193.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
8.90
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+5.1% Q1'26: +1.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+17.2% ★ Q1'26: -10.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+15.6% Q1'26: +18.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+24.9% ★ Q1'26: +21.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+18.8% ★ Q1'26: +14.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+9.3% Q1'26: +7.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.03× ★ Q1'26: 0.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
42.13M
est: 43.10B (-99.9%)
|
47.13B
est: 45.03B (+4.7%)
|
54.73B
est: 53.29B (+2.7%)
|
64.83B
est: 64.69B (+0.2%)
|
78.62B
est: 77.00B (+2.1%)
|
98.48B
est: 95.10B (+3.6%)
|
110.99B
est: 111.80B (-0.7%)
|
123.17B
est: 123.20B (0.0%)
|
152.27B
est: 152.30B (0.0%)
|
161.87B
est: 168.78B (-4.1%)
|
170.05B
est: 170.57B (-0.3%)
|
195.75B
195.75B – 195.75B
+14.8% YoY
|
215.00B
215.00B – 215.00B
+9.8% YoY
|
| EBITDA |
16.51B
est: 14.27B (+15.7%)
|
14.71B
est: 14.91B (-1.3%)
|
20.81B
est: 17.64B (+18.0%)
|
19.06B
est: 21.42B (-11.0%)
|
22.16B
est: 25.50B (-13.1%)
|
30.62B
est: 31.49B (-2.8%)
|
31.13B
est: 37.02B (-15.9%)
|
49.00B
est: 40.79B (+20.1%)
|
45.13B
est: 50.43B (-10.5%)
|
59.88B
est: 55.56B (+7.8%)
|
53.24B
est: 56.15B (-5.2%)
|
64.44B
64.44B – 64.44B
+14.8% YoY
|
70.77B
70.77B – 70.77B
+9.8% YoY
|
| EBIT |
15.00B
est: 10.34B (+45.1%)
|
12.47B
est: 10.81B (+15.4%)
|
16.57B
est: 12.79B (+29.6%)
|
11.96B
est: 15.52B (-23.0%)
|
13.27B
est: 18.48B (-28.2%)
|
20.10B
est: 22.82B (-11.9%)
|
18.86B
est: 26.83B (-29.7%)
|
37.50B
est: 29.57B (+26.9%)
|
33.86B
est: 36.55B (-7.4%)
|
48.41B
est: 53.63B (-9.7%)
|
42.33B
est: 54.20B (-21.9%)
|
62.20B
62.20B – 62.20B
+14.8% YoY
|
68.32B
68.32B – 68.32B
+9.8% YoY
|
| Net Income |
11.62M
est: 13.59B (-99.9%)
|
10.27B
est: 10.74B (-4.4%)
|
11.94B
est: 12.45B (-4.1%)
|
9.21B
est: 9.21B (0.0%)
|
10.42B
est: 13.04B (-20.1%)
|
15.08B
est: 12.30B (+22.6%)
|
9.06B
est: 12.35B (-26.6%)
|
21.09B
est: 25.72B (-18.0%)
|
24.82B
est: 25.70B (-3.4%)
|
39.26B
est: 40.18B (-2.3%)
|
49.96B
est: 52.11B (-4.1%)
|
44.37B
44.37B – 44.37B
-14.8% YoY
|
51.70B
51.70B – 51.70B
+16.5% YoY
|
| SGA |
4.13M
est: 4.57B (-99.9%)
|
4.64B
est: 4.78B (-2.9%)
|
7.56B
est: 5.65B (+33.6%)
|
9.29B
est: 6.87B (+35.3%)
|
12.92B
est: 8.17B (+58.1%)
|
13.73B
est: 10.09B (+36.0%)
|
17.42B
est: 11.86B (+46.9%)
|
9.25B
est: 13.07B (-29.3%)
|
12.72B
est: 16.16B (-21.3%)
|
12.24B
est: 13.21B (-7.3%)
|
—
est: 13.35B (-100.0%)
|
15.32B
15.32B – 15.32B
+14.8% YoY
|
16.82B
16.82B – 16.82B
+9.8% YoY
|
| EPS |
1.25
est: 1,322.02 (-99.9%)
|
1,059.36
est: 1,045.47 (+1.3%)
|
1,229.57
est: 1,211.71 (+1.5%)
|
963.24
est: 896.27 (+7.5%)
|
1,093.84
est: 1,269.06 (-13.8%)
|
1,587.10
est: 1,197.00 (+32.6%)
|
963.99
est: 1,202.00 (-19.8%)
|
2,273.79
est: 2,503.00 (-9.2%)
|
2,512.11
est: 2,500.50 (+0.5%)
|
3,795.00
est: 3,577.50 (+6.1%)
|
4,448.55
est: 4,640.00 (-4.1%)
|
3,951.00
3,951.00 – 3,951.00
-14.8% YoY
|
4,604.00
4,604.00 – 4,604.00
+16.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | S- | 5/5 | 5/5 | 5/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
46.76B
OE per share TTM
3,552.09
Owner's Yield
4.51%
Maintenance CapEx ratio
4.17%
Maint CapEx / Avg PPE
42.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 32 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex Healthcare 266420.KS | 0.16% | 70.5K | 0.09% |
| 2 | Samsung Kodex Fn Growth ETF 325010.KS | 0.02% | 17.2K | 0.30% |
| 3 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 8.0K | 0.42% |
| 4 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 31.0K | 0.44% |
| 5 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 12.5K | 0.56% |
| 6 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 59.2K | 0.46% |
| 7 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 186.1K | 0.39% |
| 8 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.00% | 7.9K | 0.33% |
| 9 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 107.0K | 0.29% |
| 10 | Vanguard FTSE Pacific ETF VPL | 0.00% | 139.5K | 0.07% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
187.31M
Shares Outstanding
10.29M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Min-jong Kang | Chief Executive Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 200670.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
